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ABSTRACT 
Objective: Qualitative risk assessment process is a new topic in the pharmaceutical industries. The main outcome of the risk assessment 
implementation is to help the manufacturers for a better decision-making, in a case that a quality problem arises. According to the ISO documents;  
vials used in the pharmaceutical industry have a special dimension specification and Quality Control analytical results should prove that the vial 
samples are in the defined range. Nevertheless, the value of these tests is not the same as defined ISO specifications;  and this may have minor 
and/or significant impact on the final product quality.  
Methods: The purpose of this qualitative study was to rank the results of the vial dimention tests based on quality risk assessment. Consequently, 
these rankings can help to decide whether the dimension deviation from quality specification of vials is acceptable and what will be the impact of 
accepting the risk on the final product safety and finally how to decrease the risk. 
For this purpose, we consider the final product contamination could be one of the main indicators for the quality as the contamination from 
packaging materials in particular are more important when aseptic processing run. 
Results: Dimensions that are directly associated with opening the vial containing d2, d3, d4 and h4 that they affect rubber sealing and capping. 
Other dimensions like h1, h2, h3 and d1 affect rubber sealing and capping indirectly. Therefore, these two groups of deviations have a very high 
probability of contamination. 
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INTRODUCTION 
Achieving a shared understanding of the application of Quality Risk 
Management (QRM) among diverse stakeholders is difficult because 
each stakeholder might identify different potential harms, place a 
different probability on each harm occurring and attribute different 
severities to each harm. In relation to pharmaceuticals, there are a 
variety of stakeholders, including patients and medical practitioners 
as well as government and industry. Here the protection of the 
patient by managing the quality risk was considered as the prime 
importance. 
According to ICH Q9 harm defines as -damage to health, including 
the damage that can occur from loss of product quality or 
availability- and quality risk management is “a systematic process 
for the assessment, control, communication and review of risks to 
the quality of the drug product across the product lifecycle” [1]. 
An effective QRM approach can further ensure the high quality of the 
pharmaceutical product to the patient by providing a proactive 
means to identify and control potential quality issues during the 
development and manufacturing process. In this regards, an 
effective QRM model provides a positive and practical approach for 
implementing preventive actions [1]. In addition, utilization of QRM 
can improve the decision making whenever a quality problem arises. 
Effective QRM can also facilitate better and more informed decisions, 
provide regulators with greater assurance of a company’s ability to 
deal with potential risks, and can beneficially affect the extent and 
level of direct regulatory oversight  
As a result of the sanctions in the recent years, supplying the raw 
materials needed for pharmaceutical industries have become a 
thorny problem. Qualitative risk assessment for raw material chain 
supply can aid manufacturers to decide whether the deviations from 
ISO specifications have a major impact on product quality or not. 
The purpose of this study was to offer a systematic approach to QRM 
for pharmaceutical vials as the first packaging materials in a high 
technology aseptic filling processing. 
MATERIALS AND METHODS 
Selection of QRM Working Team 
QRM activities are usually, but not always, undertaken by 
interdisciplinary teams. Expert team for this study were selected 
from the appropriate working areas (Authorized person, Quality 
units [QA and QC], production operations, sales and marketing) in 
addition to individuals who were knowledgeable about the QRM 
process. 
Definition of the possible risk types:   
In this study, the main aim was to investigate the predictable risks, 
including higher risks leading to environmental contamination 
during filling operations, contaminations generated by human 
intervention (e. g., machine breakdown or component transfer), 
contaminations due to breakage in glass containers and presence of 
glass particles when vials are opened, contaminations that are 
caused by defective rubber sealing and malformed capping, and 
lower risks including vial imbalance during machine-run, difficulties 
in removing the fluid with a syringe from vial and etc.  
According to International Organization for Standardization 
(ISO8362-1; 2009) [2] vial dimensions defined as shown in figure 1. 
Legally any value outside this range will cause unacceptable QC 
results. 
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Fig. 1: Schematic view and dimentions of Injection Vials made of Neutral Borosilicate Glass Tubing according to the International 
Organization for standardization (ISO8362-1; 2009) [2]. 
 
Table 1: Scoring the Severity and Frequency of the deviations to define the risks.
Capacity 
mL 
Diameter Height Thickness 
d d1 d2 d3 h4 h1 h2 h3 S4 S1 2 
basic tol. basic tol. basic tol. basic tol. basic tol. basic tol. basic tol. 
2 16.00 0.20 13.00 +0.20 
-0.30 
≤10.50 7.00 0.20 35.00 0.50 ≥23.00 8.00 0.50 3.60 0.20 1.00 0.04 ≥0.70 
4 45.00 ≥33.00 
6 22.00 20.00 ≤16.00 12.50 40.00 ≥27.00 8.50 
8 45.00 ≥32.00 
10 24.00 ≤16.50 ≥31.00 9.00 
15 60.00 ≥46.00 
20 30.00 0.30 ≤17.50 55.00 0.70 ≥35.00 10.00 0.75 1.20 0.05 
25 65.00 ≥45.00 
30 75.00 ≥55.00 
 
                   Score 
 Parameter 





implicitly by the 
applicable GMP 
Addressed by applicable GMP, but 
without possible impact on the 
manufactured product 
Possible impact on the 
manufactured product but 
without risk for the patient 
(end user) 
Possible impact on the 
manufactured product and with 





with a frequency 
lower than 10e-6 
accidental event, occurrence 
exceptional 
frequent but not systematic 
event 
event noted each time or almost 
 
Quantification The method of quantification is according to QRM – implementation 
of ICH Q9 in the pharmaceutical field (3) as listed in Table 1:
Also the Factor (N) modules the expression of the risk and is defined 
by the following way:   
• N=1.0: existence of documented evidence, established by an 
independent entity, proving the ongoing compliance to regulatory 
requirements during more than 36 months. 
• N=1.1: existence of documented evidence, established by an 
independent entity, proving the ongoing compliance to regulatory 
requirements during more than 36 months. 
• N=1.2:  absence of documented evidence, established by an 
independent entity, proving the compliance to regulatory 
requirements or existence of non-addressed non-conformity. 
After scoring the severity and frequency for each risk the systemic 
risk was calculated using the following equation:   
Rs=SFN 
To analysis the systemic risk of the following criteria are defined:   
• Low, if: 0=<R<3 
• Moderate, if: 3=<R<5 
• High if: R>=5 
It is also agreed that a risk is acceptable if it is low or it is a moderate 
and detection is certain (D=d). “N” was considered equal to 1.1 for 
our production line.  
RESULTS 
Risk assessment analysis was performed and the results are 
summarized in Table 2 The most obvious critical point is vial entry 
surface that provides a good estimate to correlate with risk of 
contamination rather than the entire internal surface of the vial 
container. Dimensions that are directly associated with an opening 
of the vials are d2, d3, d4 and h4 which in turn affect rubber sealing 
and capping. Other dimensions like h1, h2, h3 and d1 affect rubber 
sealing and capping, indirectly. Therefore the deviations in the 
specification of these two groups of dimentions have a very high 
probability of contamination risk.  
Another main surface that may potentially be contaminated is the 
external surface of container components. These surfaces are fully 
exposed to the laminar airflow and are in contact with equipment 
parts, such as the rails and ramps, which may transfer 
environmental contaminants. 
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Vial breakage caused entering such contaminations with glass 
particles into product container. On the other hand vial breakage 
during the filling process will lead to increased personnel traffic in 
the clean area to wipe off the rails from the glass particles , which in 
turn increase the possibility of contamination under laminar airflow. 
Almost all of the deviations from the standard dimensions can 
possibly lead to this risk. 
The difference in amount of “t” -arc of vial stand- could be caused by 
an imbalance of the vial during the filling process and therefore 
increase the rate of fracture. Increasing the amount of “t” dimension 
might cause difficult removal of final pharmaceutical product filled 
in the vial by syringe. 
“d1” dimension, Being outside of the specified range might lead to 
improper placement of vial for filling. It is more likely to break;  and 
also may lead to improper filling volume. 
Underweight vials, may increase the risk of contamination by 
increasing vial breakage probability. Any changes in the weight of 
vials might lead to improper filling volume, because the filler volume 
adjustment is done according to the standard vial weight. As 
specified in Table 2, weight difference deviation has the highest risk 
factor score for the aseptic filling process (Rs=9.9). Any significant 
weight distortion is very important especially when the standard 
deviation is too high. Risks resulting from this deviation couldn’t be 
accepted in the filling production line. Deviations that are related to 
the h1, h4, s1 and s2 dimensions also showed high risk scores 
(Rs
Risk score for the h2 and h3 deviations was 3.3, and this was not 
accepted. Vial’s defects i. e. breakage  are detectable 100% but rubber 
sealing defects and malformed capping may not be detected by the visual 
inspection procedure. Deviations of r1, r2, t and d1-4 dimensions  
showed acceptable risk score (0=<R
=6.6), and this risk might not be accepted. 
s
 
<3 or 3=<R<5 but D=d). 












































1. Defective rubber sealing; and malformed capping
* Product contamination 3 2 1.1 6.6 c 6.6 N
2. Possible vial breakage
*presence of glass particles when vials are opened
*Increased personnel  traffic
3 2 1.1 6.6 d 6.6 Y
1. Defective rubber sealing; and malformed capping
*Product contamination 3 1 1.1 3.3 c 3.3 N
2. Possible vial breakage
*presence of glass particles when vials are opened
*Increased personnel  traffic
3 1 1.1 3.3 d 3.3 Y
1. Defective rubber sealing; and malformed capping
*Product contamination 3 1 1.1 3.3 c 3.3 N
2. Possible vial breakage
*presence of glass particles when vials are opened
*Increased personnel  traffic
3 1 1.1 3.3 d 3.3 Y
1. Defective rubber sealing; and malformed capping
*Product contamination 3 2 1.1 6.6 c 6.6 N
2. Possible vial breakage
*presence of glass particles when vials are opened
*Increased personnel  traffic
3 2 1.1 6.6 d 6.6 Y
r1
1. Possible vial breakage
*presence of glass particles when vials are opened
*Increased personnel  traffic
3 1 1.1 3.3 d 3.3 Y
1. Possible vial breakage
*presence of glass particles when vials are opened
*Increased personnel  traffic
3 1 1.1 3.3 d 3.3 Y
2. vials imbalance 1 1 1.1 1.1 d 1.1 Y
1. Possible vial breakage
*presence of glass particles when vials are opened
*Increased personnel  traffic
3 1 1.1 3.3 d 3.3 Y
2. vials imbalance 1 2 1.1 2.2 d 2.2 Y
3. Difficulty in removing the fluid with a syringe 1 1 1.1 1.1 d 1.1 Y
d1
1. Improper placement of vials in filling station
*Improper filling volume
* Possible vial breakage and presence of glass particles when 
vials are opened
3 1 1.1 3.3 d 3.3 Y
d2
1. Malformed capping
*Product contamination 2 1 1.1 2.2 d 2.2 Y
d3
1. Malformed capping
*Product contamination 2 1 1.1 2.2 d 2.2 Y
d4
1. Defective rubber sealing
*Product contamination 3 1 1.1 3.3 d 3.3 Y
s1
1. Possible vial breakage
*presence of glass particles when vials are opened
*Increased personnel  traffic
3 2 1.1 6.6 d 6.6 N
s2
1. Possible vial breakage
*presence of glass particles when vials are opened
*Increased personnel  traffic
3 2 1.1 6.6 d 6.6 N
weight 
of vial
1. Possible vial breakage
*presence of glass particles when vials are opened
*Increased personnel  traffic


















The Cut-offs of the risk scores , are useful to scale or fit the risk 
ranking for the quality management or policy objectives. 
According to the obtained results, the final decision of risk 
assessment committee was to prepare a practical guideline for the 
commercial department management with the following topics: 
Purchasing vials with vial weight  or h1, h4, s1 and s2 
 Vials with other dimension deviations can be purchased and used 
in filling production line;  while the production personnel should 
increase certain controls applied to detect the defects. 
dimensions 
deviations , will be unauthorized by the quality system.  
 Interactive relation with domestic (national) vials manufacturers 
to correct and improve the products’ quality and their 
manufacturing process, should be considered by the commercial 
department. 
In order to ensure the quality analysis test results are validated, 
related QC laboratory equipments should be calibrated according to 
the written protocols. According to the ICH guidelines stability 
studies of thepharmaceutical injectable products are essential to 
repeat if supplier of any first packaging material like vial changed. 
On the other hand due to the recent sanctions of our country, the 
number of contracting companies are limited;  so changing the 
source of vials has its own difficulties. Therefore, such a risk-based 
assessment plans to investigate the main causes of vial failure in the 
quality control test;  dimensional deviations and vial weight are 
useful. Simulation of aseptic filling of inhectable pharmaceutical 
products is also helpful for confirmation of this conclusion [4, 5]. 
Although there are some examples of the quality risk management 
implementation in the pharmaceutical industries, these limited 
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practices do not represent the full contributions of practical risk 
management to the quality system. In addition, the importance of 
quality management systems has been recognized in the 
pharmaceutical industries, and it is becoming evident that quality 
risk management has a valuable role in this regards. 
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